Introduction
The infection of several cell types by the human immunodeficiency virus (HIV-1) has profound effects on the surface protein pattern of the host cell. Expression of a variety of cell surface molecules is modulated by infection, the most prominent being CD4, the coreceptor for MHC class II on helper T cells.
This phenomenon might be biologically relevant in several aspects:
(1) Since HIV-1 is known to acquire a lot of host cell surface molecules during the budding process, upregulation of their cell surface expression results in an increased occurrence on the viral surface. Host cell-derived molecules have at least partly been shown to retain their biological function on the viral surface and to be involved in processes like adhesion of viral particles to potential host cells (eg ICAM-1) or protection of virions against attack by the complement system (eg CD55, a negative regulator of complement activation). Consequently, a high cellular expression of certain membrane molecules is advantageous for the progenitor virions budding from this cell. The modulation of several cell surface molecules by HIV-1 as described in the literature is summarized in Table 1 . The list includes: (1) certain molecules involved in immune activation eg B7, CD7, MHC class I and II and CD4; (2) complement-related proteins like complement receptors and negative regulators of complement activation; (3) various cell adhesion molecules; (4) Fas and FasL as apoptosis-related proteins; and (5) receptors for important immune regulatory cytokines. For some of these surface molecules the viral effector protein responsible for modulatory effect is already known including the surface molecules gp120 and gp41 and the regulatory molecules Nef, Tat and Vpu. In this review we will provide a more detailed discussion about some selected examples of each group with possible effects of modulated expression on HIV-induced pathogenesis and, if known, the viral proteins responsible for the modulation.
Decreased expression of costimulatory molecules CD28 and B7
A complete T cell activation requires both T cell receptor (TCR) stimulation and costimulation by accessory molecules. Tat  CD7  not gp120 or  2  p24  MHC 1  Vpu, Nef, gp41 8-12  B7 (CD80,  13  CD86)  CD16  13  CD3  14  CD28  15,16  Complement-related CR1  17,18  proteins  CR2  19,20  CR3  21  C5aR  22  CD55 (Daf)  21,23  Adhesion molecules LFA-1 (CD1  not gp120, p24  2  la/CD18)  VLA-5  Tat  24  CD62L  25  CR3  21  Apoptosis-related  Fas  Tat, gp120  26-28  proteins  FasL  29-31  Cytokine receptors  IL-2R  Tat, gp120, nef 32-34  TNF receptor  Tat  35  IL-4R Tat 36
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The CD28 receptor on CD4 + and CD8 + T cells interacts with B7 molecules on antigen-presenting cells (APC) to generate those essential costimulatory signals. B7 includes two functionally related costimulatory molecules, B7-1 (CD80) and B7-2 (CD86). Costimulation results in cytokine production, T cell proliferation and activation of cytotoxicity.
During the progression of AIDS disease CD28 expression is lost on CD4 + and CD8 + T cells. 37 This loss is correlated with reduced responsiveness to costimulation suggesting that dysregulation of normal T cell function associated with HIV-1 infection may partly result from the loss of CD28 expression. On CD8 + T cells from HIV+ subjects the disease stage-related reduction in CD28 expression was rather strong and associated with significantly reduced proliferative response to costimulation with cell-bound anti-CD3 and B7. CD4 + T cells from the patients showed a slighter but nevertheless significant CD28 down-regulation and were also hyporesponsive to B7 co-stimulation. 38 Not only CD28 but also the ligand B7 shows an altered expression after HIV infection. Patient-derived macrophages express B7 molecules in a lower density than macrophages derived from healthy donors. 13 Monocytes that express constitutively B7 lose this marker after HIV-1 infection and become refractory to inducers of B7 synthesis. 39 This down-modulation is an indirect effect mediated by an altered IL-10 production since B7 expression can be normalized by the incubation of patient macrophages with anti-IL-10 monoclonal antibodies. 13 The decreased expression of CD28 and B7 molecules on T lymphocytes and macrophages is a critical parameter for immune dysfunction and disease progression.
Since costimulation is crucial for immune activation also novel vaccination protocols have been developed to induce HIV-1 antigen-specific immune responses by DNA vaccination. Coimmunization of CD86 and CD80 expression plasmids along with plasmid DNA harboring the genes for HIV-1 antigen induced a dramatic increase in cytotoxic T lymphocyte induction and CD4
+ proliferation when compared with HIV antigen immunization alone. 40 This stimulating effect is mediated mainly by CD86 expression and can be decreased by combination with an inhibitor of B7/CD28 costimulation. 40, 41 The approach represents a new immunization stratagy to achieve a significant enhancement of the antigenspecific cellular immune response.
Down-modulation of various complement receptors during HIV infection
Several cell types have been reported to harbor altered amounts of complement receptors CR1, CR2, CR3 or C5aR after the infection with HIV-1, including B and T cells, monocytic cells and erythrocytes. A down-modulation of surface complement receptors might be associated with disturbed immune cell activation, complement activation, HIV-associated autoimmune diseases, viral spreading and secondary infections. The mechanisms by which HIV exert its effect vary between the molecules and include activation of gene transcription and activation of protease activity.
The complement receptor type 1 (CR1)
The transmembrane complement receptor CR1 (CD35) mediates the cellular binding of invading particles or immune complexes opsonized with the complement proteins C3b and/or C4b. CR1 on erythrocytes enables these cells to transport opsonized immune complexes to phagocytic cells in liver and spleen, where the immune complexes are removed from the erythrocytic surface and engulfed by the phagocytes. 42 Moreover, CR1 is a negative regulatory protein of complement cascade activation with cofactor activity for factor I-mediated cleavage of C3b and C4b into inactive fragments. CR1 also has decay-accelerating activity for the C3 convertase of both the classical and the alternative complement activation pathway. 43, 44 B cells isolated from HIV-infected persons express significantly reduced levels of surface CR1 when compared with B cells derived from control donors. 18 This down-modulation of complement receptor I may have some effects on the ability of B cells to capture and engulf opsonized antigens for presentation to T cells. The decrease in complement receptor level in late stages of disease could thus be one factor adding to the immune dysfunction of T cells. In addition, lack of the negative regulator molecule CR1 of the complement system may contribute to increased complement activation observed in HIV patients.
On erythrocytes the number of CR1 surface molecules is also significantly decreased in symptomatic HIV-infected individuals correlating with increasing levels of circulating immune complexes and with the clinical severity of disease. 45, 46 Since reduced CR1 expression on erythrocytes has been associated with autoimmune diseases HIV-mediated down-modulation of CR1 on erythrocytes in HIV patients could also contribute to the increase of autoantibody presence noticed in infected individuals. 46 Additional studies on erythrocytes indicated that modulation of CR1 expression on those infected cells is achieved by enhanced proteolytic cleavage of the surface receptor. 17 The CR1 molecule is sensitive against proteolytic attack and CR1 fragments are found on normal erythrocytes as well. The relative amount of these fragments is increased on erythrocytes derived from AIDS patients. The mechanism for CR1 decrease on B cells is as yet unknown as well as the mechanism of protease activation by viral infection.
The complement receptor type 2 (CR2)
Complement receptor 2 (CR2, CD21) is a transmembrane polypeptide chain mainly found on B cells. Binding of C3dg-coated particles to complement receptor 2 on B cells allows association between opsonized antigen and membrane Ig, thereby triggering B cell activation. Since B cells have a major role in presenting antigen to T lymphocytes, binding of C3d-opsonized particles to CR2 on and their uptake by B cells also induces T cell activation and proliferation. 47 Furthermore, CR2 has a negative regulatory activity for the complement cascade by serving as cofactor for factor I-mediated degradation of membrane-bound iC3b. 48 After infection of the human T lymphoblastoid cell line MT2 with HIV-1 and HIV-2 isolates expression of CR2 on the cell surface is down-regulated. 19, 20 A similar decrease of CR2 has also been observed in vivo with the percent of CD4 + cells expressing CR2 being significantly decreased in HIV-infected patients compared to uninfected control donors. 49 The diminished CR2 synthesis in vivo may be assigned to an increased immune complex formation and complement activation, as demonstrated by higher levels of the complement activation fragments C3d, C4d and Ba of the classical and alternative pathway in HIV-infected individuals. 45, 50 A similar downmodulation of surface CR2 was also detectible for B cells.
18,19
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In contrast to CR1, the decreased expression of CR2 on different T and B cell lines does not result from a proteolytic cleavage but at least partly from a lower transcription level of the corresponding gene in HIV-infected cells, since a decrease is also seen on specific CR2 mRNA level in the different cells. 19 
The complement receptor type 3 (CR3)
CR3 is a heterodimeric ␤2 integrin with CD11b as ␣ chain (also called ␣ M ) and CD18 as ␤ chain. 51 It has been described as recognizing a large variety of ligands including the complement component iC3b, counter-receptors of the immunoglobulin superfamily (ICAM-1 and ICAM-2), blood coagulation factors and nonprotein ligands like ␤-glucans, LPS, heparin and proteoglycans. 52, 53 CR3 plays a central role in phagocytosis by binding to pathogens either directly via LPS or indirectly via iC3b fragments on the particle surface. CR3 is also involved in cellular adherence to activated endothelial cells or to coagulation factors like fibrinogen and factor X. Cellular homotypic aggregation, migration and chemotaxis are further processes in which CR3 molecules are involved. In addition, CR3 mediates transmembrane chemical signaling, also for associated glycosylphosphatidylinositol-anchored molecules.
Whereas CR1 and CR2 are down-modulated in their expression by HIV, infection of T cells and monocytic cells results in an up-regulation of CD18 production, the ␤-chain for CR3. A consequence of this increased expression might be enhanced attachment of leukocytes to blood vessel endothelial cells and, consequently, increased viral spreading throughout the body.
Since CD18 up-regulation was visible both on protein and on mRNA levels, a mechanism on the transcriptional level is a probability. Present experiments aim at clarifying the question, which viral protein exerts this effect. 21 The complement receptor for C5a (C5aR) Not only receptors for various fragments of the complement protein C3 are modulated by HIV-1. Normal monocytes, either infected with HIV-1 or exposed to the HIV envelope protein gp120 in vitro exhibited a marked reduction in the expression of C5a receptor. 22 The anaphylatoxin C5a is the aminoterminal cationic fragment of the ␣ chain of complement protein C5, elicits chemotaxis of cells of all myeloid lineages and causes vascular permeability. 54 The down-modulation of the C5a receptor synthesis by HIV-1 correlates with a striking impairment of chemotactic response to inflammatory chemotactic stimuli. 22 This phenomenon could contribute to the increased occurrence of secondary infections in the late stages of disease. The exact mechanism of C5aR down-modulation is not known.
Modulation of various cell adhesion molecules
Leukocytes express various adhesion promoting receptors which mediate cell-cell and cell-matrix interactions. These adhesive interactions are crucial to the regulation of hematopoiesis and thymocyte maturation, the direction and control of leukocyte traffic and migration through tissues and to the development of effective immune and non-immune inflammatory response. Four basic classes of adhesion molecules are described: selectins, integrins, immunoglobulin superfamily members and proteoglycans. A modulation of adhesion molecule expression is a critical parameter for viral spreading and viral localization throughout the body.
Upregulation of L-selectin
Selectins and their ligands participate primarily in leukocyte exit from the blood into lymph nodes, peripheral tissues or sites of inflammation. They are specialized to initiate a rapid interaction between leukocytes and activated endothelial cells under conditions of constant blood flow, leading to rolling of leukocytes on the underlying endothelium. 55 Besides, L-selectin (CD62L) is the homing receptor for lymphocytes to high endothelial venules in the peripheral lymph nodes. 56 L-selectin recognizes sialylated sulfated oligosaccharides, eg Glycam-1, CD15s and CD34.
Exposure of resting CD4 + T lymphocytes to HIV-1 transiently up-regulates expression of cell surface CD62L in peripheral blood lymphocytes with concomitant enhanced ability to bind to lymph node high endothelial venules in an ex vivo homing assay. Although the effect is predominantly observed in CD4
+ cells, an up-regulation is also found, to a lesser degree, in CD8 + lymphocytes. 25 This effect of HIV on lymphocytes might contribute to the apparent localization of HIVinfected cells in lymphoid organs and the observed lymphadenopathy of HIV-infected patients. Neither details of the mechanism nor the viral protein exerting this up-modulation are presently known.
Up-regulation of ␤2 integrins
After selectin-mediated initial rolling interaction between leukocyte and endothelium a high avidity state of leukocyte surface integrins is activated leading to a tight and stable interaction with their endothelial immunoglobulin superfamiliy ligands. For this stable interaction the ␤2 integrins LFA-1 and CR3 play a key role.
The cellular adhesion molecule LFA-1 (lymphocyte function-associated antigen 1) is a heterodimeric ␤2 integrin with CD11a as ␣ chain and CD18 as ␤ chain. 57 It is important for numerous lymphocyte functions, including cytotoxic T lymphocyte and natural killer cell cytotoxicity, antigen presentation and adhesion of lymphocytes to the blood vessel endothelium. LFA-1 binds to its counter-receptor ICAM-1 (intercellular adhesion molecule 1; CD54), a member of the immunoglobulin superfamily participating in T cell adhesive interactions. The expression of LFA-1 on hematopoietic cells is dramatically increased at sites of inflammation, providing important means of regulating cell-cell interactions and thereby inflammatory responses. 58 HIV modulates the expression of LFA-1 on various cell types. LFA-1 is induced both in cytoplasm and at the cell surface after infection of T lymphoblastoid cells with HIV-1. Also on patient peripheral blood lymphocytes (PBL) the production of LFA-1 was up-regulated in parallel with the disease progression. 59 Similarly, HIV infection of monocytes resulted in an elevated expression of adhesion molecule LFA-1 with homotypic aggregation of monocytes visible already 2 h after exposure to the virus. 60 The regulatory mechanism is unclear, but seems not to involve viral expression. The effect is not reproducible by addition of envelope protein gp 120.
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The ␤2 integrin CR3 is not only a receptor for C3 fragments, but, as mentioned above, also participates in cellular adherence to activated endothelial cells. It shares with LFA-1 the ability to act as a counter-receptor for ICAM-1 and to mediate final adhesion of leukocytes to activated endothelium after the rolling process. Up-regulation of CR3 on different cell lines after infection with HIV-1 is described above. The modulation of CD18 mRNA level indicates a mechanism on the transcriptional level. 21 An enhanced expression of LFA-1 and CR3 on the surface of virus-infected cells might be advantageous for HIV in several respects. LFA-1, CR3 and ICAM-1 are present on the viral surface and LFA-1 and ICAM-1 have also been demonstrated to contribute to viral infectivity. Antibodies against LFA-1 and ICAM-1 markedly decreased the infectivity, indicating a functional relevance of adhesion molecules on the viral surface for the adsorption to susceptible cells displaying the corresponding counterligand. 61 Since interaction between ␤2 integrin family and ICAM-1 is required for leukocyte migration and is responsible for strengthening and stabilizing leukocyte adhesion on the endothelium of the blood vessels, high expression of those adhesion molecules could also favor spreading of virus-infected cells in the body. In addition, since cellular adherence has important intracellular signalling function, up-regulation of adhesion receptors has the potential to enhance human immunodeficiency virus replication in monocytic cells.
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Modulation of apoptosis-related molecules by HIV-1
Fas (CD95; APO-1) is a cellular transmembrane protein which, after interaction with its ligand FasL, is involved in the mediation of apoptosis-triggering signals. Interaction between Fas and FasL plays an obligatory role in apoptosis of T cells that is triggered by repeated activation and TCR engagement, so-called activation-induced cell death (AICD). 63, 64 If activated T cells are re-stimulated via their antigen receptors, they co-express Fas and FasL and rapidly undergo apoptosis. This pathway is important for elimination of self-reactive lymphocytes and thus for prevention of autoimmunity. The Fas pathway is also one of two lytic mechanisms utilized by cytotoxic T lymphocytes expressing FasL to kill CD95-bearing target cells. 65 Fas is not only involved in cell death; Fas engagement in T cells may also yield a costimulatory signal, enhancing T cell receptor-mediated proliferation, membrane expression of activation antigens and cytokine secretion. 66 The molecular basis whereby engagement of the Fas receptor may be perceived either as a costimulatory or as a death signal is poorly understood. Different second messengers or a different cellular 'background' such as differentiation status might play a role.
Fas and FasL has been reported to be up-regulated by HIVinfection in different cell types. CD4
+ and CD8 + lymphocytes derived from HIV-infected patients show increased CD95 expression compared with cells from uninfected individuals. 67, 68 Within the HIV-positive group the increase in Fas expression was correlated with a decline in CD4 count and other parameters of disease progression. [67] [68] [69] [70] A functional relevance of Fas upregulation could also be demonstrated in vitro with apoptosis of CD4 + cells as a consequence of Fas triggering by agonistic anti-Fas monoclonal antibody being more pronounced in lymphocytes derived from HIV+ than from uninfected individuals. Furthermore, Fas triggering of lymphocytes from HIV-infected persons increases the levels of interleukin-1beta converting enzyme (ICE), a protein associated with apoptosis. 71 For Fas ligand, an up-regulation of the expression has been reported in most experimental systems. 30 After retroviral therapy, the Fas ligand expression in T cells from HIV-infected children is down-regulated. 31 The mediation of apoptosis by Fas may be dependent on the presence of monocytes in the culture, since apoptosis of isolated activated CD4 + T cell lines seems to be Fas/FasLindependent. 72, 73 In B cells the HIV-encoded transactivator Tat induces Fas expression, suggesting a contribution of Tat to activationinduced Fas-mediated B cell death during late stage of HIV-1 infection. 28 Since an increase is also observed on mRNA level, an effect on the transcriptional level is likely. Similarly, mRNA for FasL in PBMC from HIV seropositive individuals is markedly up-regulated. 30 However, additional mechanisms of Fas up-regulation by HIV obviously exist. It has been shown that CD4 crosslinking (CD4XL) by HIV-envelope protein gp 120 or a monoclonal anti-CD4 antibody results in augmentation of Fas antigen expression in CD4
+ and CD8 + T cells and consequently in apoptosis of the cells. 26, [74] [75] [76] The CD4XL-induced apoptosis seems to be accessory cell-dependent with monocytes playing a critical role. CD4XL in monocytes results in expression of Fas ligand, thereby presumably enabling interaction between Fas on CD4 + cells and monocyte-derived Fas ligand to induce T cell apoptosis. 76 Similar up-regulation is observed in HIVinfected macrophages. 29 Interruption of the Fas-FasL interaction by blocking antibodies abrogates the HIV-infected macrophage-dependent death of T lymphocytes.
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Altered expression of the cytokine IL-2 receptor IL-2 is the major cytokine for proliferation and differentiation of T lymphocytes, thereby stimulating the generation of cellular immunity, and has an activating effect on macrophage function. Besides, it increases the cytolytic activity of NK cells and promotes the development of lymphokine-activated killer cells. 77 The strength of an immune response is determined to a large extent by the amount of IL-2 elicited by a stimulus. In vivo studies showed a significantly reduced number of IL-2 producing T cell clones in AIDS patients. 78 Since T cells from HIV-1-infected individuals are impaired in their capacity to produce IL-2, necessary for intact T cell proliferative responses, treatment with IL-2 is a logical form of immune therapy. Several studies have been published on IL-2 therapy, all in individuals treated simultaneously with anti-viral drugs to inhibit viral replication. Low-dose treatment was demonstrated to increase immune functions without higher viral load. Significant increase was detectable in CD4 cell count, NK activity and HIV-specific cytotoxicity. [79] [80] [81] However, effects were most significant in individuals with high CD4 counts and less pronounced in patients with low CD4 numbers. 82 Two explanations are likely to be responsible for the minor success of IL-2 therapy in some patients groups: down-modulation of surface IL-2 receptor expression and increased serum levels of soluble IL-2 receptor. CD4 + T lymphocytes isolated from HIV-infected patients only marginally express beta and gamma chains of interleukin-2 receptor when compared with control cells from uninfected donors. 83 Whereas mitogenic stimulation of CD4 + and CD8 + cells from healthy donors increases surface expression of IL-2R no up-modulation is found on cells derived from HIVpositive donors. The reduction in high affinity IL-2R S103 expression correlated with the reduced proliferative response after addition of exogenous IL-2, 84 thereby contributing to the disturbed immune function and T cell activation observed in HIV-infected patients. Several viral proteins were shown to contribute to altered IL-2R surface expression: treatment of cells with gp 120 impedes IL-2R beta and gamma subunit expression; 83 similarly mitogen-induced IL-2R alpha and beta chain surface expression was significantly decreased in tattransfected cells compared to control cells; 32 and also Nef expression in T cells and PHA activation of PBMC reduced their expression of IL-2R to background levels. 34 The HIVinduced loss of IL-2R surface expression on T cells is a severe problem in IL-2-based cytokine therapy of HIV patients.
Summary and conclusions
The examples discussed above show the profound influence of HIV infection on expression pattern of cell surface proteins and the functional relevance thereof. Altered cell surface pattern is involved in all aspects of HIV-induced pathogenesis such as viral spreading viral adhesion and cellular apoptosis and is an important parameter for therapeutical approaches. The regulatory mechanism is not homogenous for all proteins but includes divergent effects like modulation of gene transcription and proteolytic cleavage.
Modulation by viral infection might be either a direct or an indirect effect. Various viral proteins have been implicated in direct modulation like the regulatory proteins Tat, Nef and Vpu, but also the envelope proteins gp 120 and gp41. In addition, infection by HIV-1 has been shown to modulate expression of various cytokines including IL-10 and IFN-␥. 85 The altered expression of various surface proteins might be an indirect effect of cytokines acting on B cells, T cells and monocytic cells.
By virus capture assays the presence of further proteins on viral surface was demonstrated indicating a possible function for viral life cycle. To study the modulation of expression of those additional important surface molecules by HIV and its biological function for the pathogenesis will be the aim of further studies in our laboratory.
